Processing

Please wait...

Settings

Settings

1. WO1991000741 - USE OF BLUETONGUE VIRUS PROTEINS AS VACCINE COMPONENTS

Some content of this application is unavailable at the moment. If this situation persists, please contact us here
Publication Number WO/1991/000741
Publication Date 24.01.1991
International Application No. PCT/GB1990/001047
International Filing Date 06.07.1990
Chapter 2 Demand Filed 23.01.1991
IPC
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C07K 14/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
14Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
CPC
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C12N 2720/12122
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2720dsRNA Viruses
00011dsRNA Viruses
12011Reoviridae
12111Orbivirus, e.g. bluetongue virus
12122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2720/12134
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2720dsRNA Viruses
00011dsRNA Viruses
12011Reoviridae
12111Orbivirus, e.g. bluetongue virus
12134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Y10S 977/803
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
977Nanotechnology
70Nanostructure
788Of specified organic or carbon-based composition
802Virus-based particle
803Containing biological material in its interior
Y10S 977/915
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
977Nanotechnology
902Specified use of nanostructure
904for medical, immunological, body treatment, or diagnosis
915Therapeutic or pharmaceutical composition
Applicants
  • NATURAL ENVIRONMENT RESEARCH COUNCIL [GB/GB]; Polaris House North Star Avenue Swindon SN2 1EU, GB (AllExceptUS)
  • OXFORD VIROLOGY PLC [GB/GB]; 10-12 Russell Square London WC1B 5AE, GB (AllExceptUS)
  • ROY, Polly [GB/GB]; GB (UsOnly)
  • FRENCH, Timothy, John [GB/GB]; GB (UsOnly)
Inventors
  • ROY, Polly; GB
  • FRENCH, Timothy, John; GB
Agents
  • RITTER, Stephen, David; Mathys & Squire 10 Fleet Street London EC4Y 1AY, GB
Priority Data
8915572.507.07.1989GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) USE OF BLUETONGUE VIRUS PROTEINS AS VACCINE COMPONENTS
(FR) UTILISATION DE PROTEINES DU VIRUS 'BLUE TONGUE' COMME CONSTITUANTS DE VACCIN
Abstract
(EN)
A protective effect against bluetongue infection in susceptible mammals which is obtained by inoculating said mammals with a polypeptide comprising at least an antigenic portion of bluetongue virus structural protein VP2 in antigenic form produced by transforming a host with a recombinant expression vector having a DNA segment coding for said polypeptide.
(FR)
On obtient un effet de protection contre l'infection par le virus 'blue tongue' chez des mammifères qui y sont sensibles, en leur inoculant un polypeptide contenant au moins une partie antigénique de la protéine structurale VP2 du virus 'blue tongue' sous forme antigénique produite par transformation d'un hôte à l'aide d'un vecteur d'expression recombinant ayant un segment d'ADN codant pour ledit polypeptide.
Also published as
Other related publications
Latest bibliographic data on file with the International Bureau